Skip to main content
. 2015 Jun 5;5(6):e007527. doi: 10.1136/bmjopen-2014-007527

Table 6.

Pairwise difference (95% CrI) for letters gained from baseline (random treatment effects model)

Comparator Sham Ranibizumab 0.5 mg PRN Aflibercept 2q4 Laser photocoagulation Dexamethasone 0.7 mg implant Ranibizumab 0.5 mg PRN+laser photocoagulation
Sham
Ranibizumab 0.5 mg PRN 10.6 (6.9 to 14.2)*
Aflibercept 2q4 9.2 (1.7 to 16.1)* −1.4 (−8.5 to 5.2)
Laser photocoagulation −1.0 (−5.9 to 3.5) −11.5 (−15.9 to −7.5)* −10.2 (−15.5 to 4.6)*
Dexamethasone 0.7 mg implant 2.5 (−1.1 to 6.3) −8.0 (−11.9 to −4.0)* −6.7 (−14.0 to 1.3) 3.5 (−1.6 to 9.1)
Ranibizumab 0.5 mg PRN+laser photocoagulation 9.2 (3.4 to 14.5)* −1.4 (−6.3 to 3.1) −0.0 (−7.4 to 7.6) 10.1 (5.1 to 15.3)* 6.6 (0.4 to 12.3)

*p<0.05.

2q4, 2 mg monthly; CrI, credible interval; PRN, pro re nata (as needed).